Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-04-25 7:39 pm Sale | 13G | Trevi Therapeutics Inc. TRVI | Rosalind Advisors Inc. | 926,016 1.34% | -1,573,977 (-62.96%) | View |
| 2024-02-14 8:47 pm Purchase | 13G | Trevi Therapeutics Inc. TRVI | Venrock Healthcare Capital Partners II L.P. | 6,707,564 9.99% | 395,372 (+6.26%) | View |
| 2024-02-14 3:48 pm Sale | 13G | Trevi Therapeutics Inc. TRVI | Fairmount Funds Management LLC | 0 0% | -6,018,465 (Position Closed) | View |
| 2024-02-14 10:21 am Purchase | 13G | Trevi Therapeutics Inc. TRVI | VIKING GLOBAL INVESTORS LP | 6,599,062 9.99% | 436,700 (+7.09%) | View |
| 2024-02-12 06:06 am Unchanged | 13G | Trevi Therapeutics Inc. TRVI | Rubric Capital Management LP | 5,684,420 8.9% | 0 (Unchanged) | View |
| 2023-02-15 1:16 pm Purchase | 13G | Trevi Therapeutics Inc. TRVI | Rosalind Advisors Inc. | 2,499,993 4.2% | 314,329 (+14.38%) | View |
| 2023-02-14 4:55 pm Purchase | 13G | Trevi Therapeutics Inc. TRVI | Venrock Healthcare Capital Partners II L.P. | 6,312,192 9.99% | 2,643,858 (+72.07%) | View |
| 2023-02-14 3:45 pm Purchase | 13G | Trevi Therapeutics Inc. TRVI | Fairmount Funds Management LLC | 6,018,465 9.9% | 2,258,955 (+60.09%) | View |
| 2023-02-14 1:37 pm Purchase | 13G | Trevi Therapeutics Inc. TRVI | ARMISTICE CAPITAL LLC | 3,147,200 4.99% | 446,401 (+16.53%) | View |
| 2023-02-14 1:18 pm Purchase | 13G | Trevi Therapeutics Inc. TRVI | VIKING GLOBAL INVESTORS LP | 6,162,362 9.99% | 177,628 (+2.97%) | View |
| 2023-02-10 4:25 pm Sale | 13G | Trevi Therapeutics Inc. TRVI | TPG GP A LLC | 0 0% | -4,824,883 (Position Closed) | View |
| 2023-02-10 4:00 pm Purchase | 13G | Trevi Therapeutics Inc. TRVI | Rubric Capital Management LP | 5,684,420 9.49% | 5,684,420 (New Position) | View |
| 2022-10-07 5:29 pm Purchase | 13G | Trevi Therapeutics Inc. TRVI | VIKING GLOBAL INVESTORS LP | 5,984,734 9.99% | 5,984,734 (New Position) | View |
| 2022-10-07 2:51 pm Purchase | 13G | Trevi Therapeutics Inc. TRVI | Frazier Life Sciences Public Fund L.P. | 6,663,590 11.4% | 2,847,131 (+74.60%) | View |
| 2022-04-25 5:04 pm Purchase | 13D | Trevi Therapeutics Inc. TRVI | New Enterprise Associates 16 L.P. | 14,370,376 42.5% | 6,580,526 (+84.48%) | View |
| 2022-04-21 4:05 pm Purchase | 13G | Trevi Therapeutics Inc. TRVI | Venrock Healthcare Capital Partners II L.P. | 3,668,334 9.99% | 3,668,334 (New Position) | View |
| 2022-04-21 10:00 am Purchase | 13G | Trevi Therapeutics Inc. TRVI | Fairmount Funds Management LLC | 3,759,510 9.9% | 3,759,510 (New Position) | View |
| 2022-04-18 1:32 pm Purchase | 13G | Trevi Therapeutics Inc. TRVI | Frazier Life Sciences Public Fund L.P. | 3,816,459 10% | 3,816,459 (New Position) | View |
| 2022-04-08 10:41 am Purchase | 13G | Trevi Therapeutics Inc. TRVI | MAI Capital Management | 1,541,471 5% | 1,541,471 (New Position) | View |
| 2022-03-09 5:09 pm Purchase | 13G | Trevi Therapeutics Inc. TRVI | Rosalind Advisors Inc. | 2,185,664 8.5% | 2,185,664 (New Position) | View |